Emmaus Life Sciences, Inc. (EMMA): Cost of Revenue
$857.0K
Year ended 2025-12-31
$994.0K
Trailing 12 months to 2026-06-30
-30.8%
3-year compound annual growth
-17.5%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $857.0K | -28.6% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $1.20M | -10.5% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $1.34M | -48.1% | 2025-04-14, From 2023-01-01 |
| 2022-12-31 | $2.59M | -21.9% | 2024-07-03, From 2022-01-01 |
| 2021-12-31 | $3.31M | +47.3% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $2.25M | +105.5% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $1.09M | +10.2% | 2021-08-10, From 2019-01-01 |
| 2018-12-31 | $993.0K | n/a | 2021-01-25, From 2018-01-01 |
| No annual figure between 2017-09-30 and 2018-12-31. | |||
| 2017-09-30 | $53.5K | +872.7% | 2018-12-11, From 2016-10-01 |
| 2016-09-30 | $5.5K | +12.2% | 2017-12-29, From 2015-10-01 |
| 2015-09-30 | $4.9K | -93.3% | 2016-12-22, From 2014-10-01 |
| 2014-09-30 | $73.0K | n/a | 2016-01-05, From 2013-10-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $857.0K | -28.6% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $6.64M | -14.5% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $3.77M | +93.0% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $7.04M | -17.6% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $2.39M | +402.7% |
| uniQure N.V. (QURE) | 2025-12-31 | $1.69M | +33.1% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.03M | +7.1% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $2.09M | -25.1% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $4.62M | +20.4% |
Compare EMMA, TNXP, JAGX, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗